2seventy bio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

2seventy bio yıllık ortalama 8.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual. Gelirler yılda ortalama 22.5% oranında büyüyor .

Anahtar bilgiler

8.9%

Kazanç büyüme oranı

28.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	22.5%
Özkaynak getirisi	-66.5%
Net Marj	-354.2%
Sonraki Kazanç Güncellemesi	12 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Oct 03

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Jul 04

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

May 11

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Apr 03

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

Mar 07

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Feb 06

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

Jan 17

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

Dec 13

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

May 05

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

Mar 21

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Mar 19

Time To Worry? Analysts Just Downgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Outlook

Aug 12

2seventy bio GAAP EPS of -$2.02 misses by $0.09, revenue of $13.48M misses by $3.04M

Aug 10

Gelir ve Gider Dağılımı

2seventy bio nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:TSVT Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	44	-156	52
31 Mar 24	71	-223	61
31 Dec 23	100	-218	69
30 Sep 23	146	-184	72
30 Jun 23	147	-180	79
31 Mar 23	125	-215	76
31 Dec 22	91	-254	79
30 Sep 22	51	-292	85
30 Jun 22	57	-284	89
31 Mar 22	51	-291	93
31 Dec 21	55	-292	94
30 Sep 21	48	-308	91
30 Jun 21	48	-320	90
31 Mar 21	150	-222	92
31 Dec 20	248	-120	91
31 Dec 19	44	-321	82
31 Dec 18	55	-200	54

Kaliteli Kazançlar: TSVT şu anda kârlı değil.

Büyüyen Kar Marjı: TSVT şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: TSVT kârlı değildir, ancak son 5 yılda zararlarını yılda 8.9% oranında azaltmıştır.

Büyüme Hızlandırma: TSVT 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: TSVT kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 13.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: TSVT hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -66.55% ) sahiptir.

2seventy bio Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

2seventy bio, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

Third quarter 2023 earnings released: US$1.40 loss per share (vs US$1.76 loss in 3Q 2022)

Recent updates

2seventy bio, Inc. to Report Q3, 2024 Results on Nov 14, 2024

There's No Escaping 2seventy bio, Inc.'s (NASDAQ:TSVT) Muted Revenues

Consensus estimates of losses per share improve by 11%

Price target decreased by 25% to US$8.25

Consensus EPS estimates upgraded to US$1.08 loss, revenue downgraded

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Forecast to breakeven in 2026

2seventy bio, Inc.'s (NASDAQ:TSVT) Share Price Is Matching Sentiment Around Its Revenues

Consensus revenue estimates increase by 16%

New minor risk - Profitability

Downgrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near Term

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

Consensus revenue estimates fall by 24%

New minor risk - Shareholder dilution

These Analysts Just Made A Massive Downgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) EPS Forecasts

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.40 loss per share (vs US$1.76 loss in 3Q 2022)

Forecast to breakeven in 2025

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

2seventy bio, Inc. (NASDAQ:TSVT) Held Back By Insufficient Growth Even After Shares Climb 49%

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

Price target increased by 33% to US$10.67

2seventy bio, Inc. Announces Executive and Board Changes

Here's Why We're Watching 2seventy bio's (NASDAQ:TSVT) Cash Burn Situation

President recently sold US$280k worth of stock

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

2seventy bio, Inc. (NASDAQ:TSVT) Shares Fly 44% But Investors Aren't Buying For Growth

High number of new and inexperienced directors

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2Seventy Bio, Inc. Does Not Expect to Achieve the Original Revenue Guidance for 2023

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces Resignation of Nick Leschly as CEO

President recently sold US$51k worth of stock

Consensus estimates of losses per share improve by 15%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President recently sold US$55k worth of stock

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target decreased by 11% to US$25.00

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Industry Analysts Just Made A Dazzling Upgrade To Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts

Consensus revenue estimates increase by 33%

Consensus revenue estimates increase by 12%

Industry Analysts Just Upgraded Their 2seventy bio, Inc. (NASDAQ:TSVT) Revenue Forecasts By 12%

2seventy bio, Inc. (NASDAQ:TSVT) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

President recently sold US$69k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

Chief Operating Officer recently sold US$108k worth of stock

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

We're Keeping An Eye On 2seventy bio's (NASDAQ:TSVT) Cash Burn Rate

2seventy Bio: This Spinoff In The CAR-T Space Is Attractive

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients